NASDAQ:VRNA - Verona Pharma Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $19.00
  • Forecasted Upside: 116.89 %
  • Number of Analysts: 3
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 3 Buy Ratings
  • 0 Strong Buy Ratings
$8.76
▼ -0.03 (-0.34%)
1 month | 3 months | 12 months
Get New Verona Pharma Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for VRNA and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for VRNA

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$19.00
▲ +116.89% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for Verona Pharma in the last 3 months. The average price target is $19.00, with a high forecast of $23.00 and a low forecast of $17.00. The average price target represents a 116.89% upside from the last price of $8.76.
Buy
The current consensus among 3 contributing investment analysts is to buy stock in Verona Pharma. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/13/2019
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/12/2019
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/11/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/9/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/7/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/6/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/4/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/6/2021

Latest Recommendations

  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
11/30/2020WedbushReiterated RatingBuyLow
i
8/25/2020Jefferies Financial GroupInitiated CoverageBuy$17.00High
i
8/10/2020Canaccord GenuityInitiated CoverageBuy$17.00High
i
7/22/2020WedbushReiterated RatingBuy$23.00Low
i
Rating by Liana Moussatos at Wedbush
4/21/2020WedbushLower Price TargetOutperform$60.00 ➝ $50.00High
i
Rating by Liana Moussatos at Wedbush
3/31/2020WedbushReiterated RatingBuy$60.00High
i
Rating by Liana Moussatos at Wedbush
2/28/2020WedbushReiterated RatingBuy$60.00Low
i
Rating by Liana Moussatos at Wedbush
2/14/2020WedbushReiterated RatingBuy$60.00N/A
i
Rating by Liana Moussatos at Wedbush
1/14/2020SunTrust BanksBoost Price TargetBuy ➝ Buy$29.00 ➝ $34.00High
i
1/13/2020WedbushBoost Price TargetOutperform$58.00 ➝ $60.00High
i
Rating by Liana Moussatos at Wedbush
12/13/2019WedbushReiterated RatingBuy$58.00Low
i
Rating by Liana Moussatos at Wedbush
10/15/2019WedbushReiterated RatingBuyLow
i
Rating by Liana Moussatos at Wedbush
9/19/2019WedbushReiterated RatingBuy$58.00High
i
Rating by Liana Moussatos at Wedbush
7/29/2019WedbushReiterated RatingOutperform$58.00High
i
Rating by Liana Moussatos at Wedbush
5/20/2019WedbushSet Price TargetBuy$58.00Low
i
Rating by Liana Moussatos at Wedbush
5/13/2019WedbushReiterated RatingOutperform$56.00 ➝ $58.00Low
i
Rating by Liana Moussatos at Wedbush
4/17/2019BTIG ResearchInitiated CoverageBuy ➝ Buy$17.00High
i
1/14/2019WedbushReiterated RatingBuyHigh
i
Rating by Liana Moussatos at Wedbush
12/27/2018WedbushSet Price TargetBuy$56.00Low
i
Rating by Liana Moussatos at Wedbush
10/16/2018WedbushSet Price TargetBuy$56.00Low
i
Rating by Liana Moussatos at Wedbush
9/19/2018WedbushReiterated RatingBuy$56.00High
i
Rating by Liana Moussatos at Wedbush
8/10/2018Jefferies Financial GroupReiterated RatingBuy$26.00Low
i
8/7/2018WedbushSet Price TargetBuy$56.00High
i
Rating by Liana Moussatos at Wedbush
3/27/2018WedbushReiterated RatingOutperform ➝ Outperform$48.00 ➝ $55.00High
i
3/26/2018SunTrust BanksBoost Price TargetBuy ➝ Buy$26.00 ➝ $37.00High
i
3/2/2018Stifel NicolausSet Price TargetBuy$25.00Low
i
Rating by Alex Schwartz at Stifel Nicolaus
2/20/2018Berenberg BankInitiated CoverageBuy ➝ Buy$30.00High
i
2/13/2018WedbushReiterated RatingOutperform$33.00Low
i
12/8/2017WedbushReiterated RatingBuy$33.00Low
i
9/8/2017WedbushReiterated RatingOutperform$33.00Low
i
5/22/2017Jefferies Financial GroupReiterated RatingBuy$26.00High
i
5/22/2017WedbushInitiated CoverageOutperform ➝ Outperform$25.00High
i
5/22/2017SunTrust BanksInitiated CoverageBuy ➝ Buy$26.00High
i
5/22/2017Stifel NicolausInitiated CoverageBuy ➝ Buy$22.00High
i
(Data available from 3/6/2016 forward)
Verona Pharma logo
Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on develops and commercializes therapies for the treatment of respiratory diseases with unmet medical needs. Its product candidate, ensifentrine (RPL554), is an inhaled, dual inhibitor of the enzymes phosphodiesterase 3 and 4 that acts as both a bronchodilator and an anti-inflammatory agent in a single compound. The formulations of ensifentrine are under development for the treatment chronic obstructive pulmonary disease (COPD): nebulized ensifentrine is in Phase 2b clinical development for the maintenance treatment of COPD; and a dry powder inhaler and a pressurized metered-dose inhaler. The company also focuses on developing ensifentrine for the treatment of cystic fibrosis and asthma. Verona Pharma plc was founded in 2005 and is headquartered in London, the United Kingdom.
Read More

Today's Range

Now: $8.76
$8.45
$8.80

50 Day Range

MA: $8.43
$7.50
$9.33

52 Week Range

Now: $8.76
$2.01
$15.71

Volume

92,639 shs

Average Volume

161,233 shs

Market Capitalization

$115.33 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.4

Frequently Asked Questions

What sell-side analysts currently cover shares of Verona Pharma?

The following sell-side analysts have issued stock ratings on Verona Pharma in the last twelve months: Canaccord Genuity, Jefferies Financial Group Inc., Wedbush, and Zacks Investment Research.
View the latest analyst ratings for VRNA.

What is the current price target for Verona Pharma?

3 Wall Street analysts have set twelve-month price targets for Verona Pharma in the last year. Their average twelve-month price target is $19.00, suggesting a possible upside of 116.9%. Wedbush has the highest price target set, predicting VRNA will reach $23.00 in the next twelve months. Canaccord Genuity has the lowest price target set, forecasting a price of $17.00 for Verona Pharma in the next year.
View the latest price targets for VRNA.

What is the current consensus analyst rating for Verona Pharma?

Verona Pharma currently has 3 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe VRNA will outperform the market and that investors should add to their positions of Verona Pharma.
View the latest ratings for VRNA.

What other companies compete with Verona Pharma?

How do I contact Verona Pharma's investor relations team?

Verona Pharma's physical mailing address is 3 MORE LONDON RIVERSIDE, LONDON X0, SE1 2RE. The company's listed phone number is 44-20-3283-4200 and its investor relations email address is [email protected] The official website for Verona Pharma is www.veronapharma.com.